A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
How SMEs succeed in a risk averse market and win in China (free)
Publication date: Jan 28, 2014 03:09 PM
Start: Feb 27, 2014 05:00 PM
Location: Archaeology G06 LT, Torrington Place, London, WC1E 7JE
A Successful Case Study – ImmunoBiology Ltd
In this case study, we will summarise our approach. This will cover the three key bases of: securing funding, working in Emergent Markets and addressing the development requirements.
17.30-17.45 Introductions: Eli Keshavarz-Moore, UCL
18.00-18.15 Chair, Tarit Mukhopadhyay, UCL
18.15-19.15 Graham Clarke
19.30 Networking Reception
This event is without charge but space is limited and pre-booking is essential.
To register please contact Dr Karen Smith, Director of Bioprocess Leadership on +44 (0)20 7679 4411 or email email@example.com